Tagged: biomarker
4 results
Shidong Jia
Shidong Jia, MD, PhD, is the founder and global CEO of Predicine, a Silicon Valley precision-oncology company building multi-omic liquid biopsy tests that read cancer from blood and urine. Trained as a physician-scientist at Harbin Medical University, Peking Union Medical College, Dana-Farber and Harvard, he ran oncology biomarker strategy at Genentech before leaving to start Predicine in 2015. His pitch is simple: precision diagnostics to enable precision medicine, built 'From Pharma, For Pharma.'
PointCross Life Sciences
PointCross Life Sciences is a Foster City, California software and services company that turns the messy data of drug development into FDA-ready submissions. Through its XBIOM platform and eDataValidator, it standardizes nonclinical and clinical study data to CDISC SEND, SDTM and ADaM formats, runs a Hadoop-based data repository for sponsors, and supplies the U.S. FDA itself with the software reviewers use to read nonclinical submissions. The company quietly powers roughly a quarter of all FDA SEND submissions.
Seneca Therapeutics, Inc.
Seneca Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncolytic immunotherapeutics built on SVV-001, a non-pathogenic Seneca Valley Virus that selectively replicates in solid-tumor cells expressing the TEM8/ANTXR1 receptor. Founded by oncolytic-virus pioneer Dr. Paul Hallenbeck, the company pairs SVV-001 with immune modulators and checkpoint inhibitors to spark systemic anti-tumor immunity, and is advancing a Phase I/II trial in high-grade neuroendocrine neoplasms while building a pipeline of armed and neo-antigen viral constructs.
Andre Esteva
Andre Esteva, PhD, is the co-founder and CEO of ArteraAI, a medical AI company whose test for personalizing prostate cancer therapy is included in NCCN clinical guidelines, reimbursed by Medicare, and deployed internationally. A Stanford-trained AI scientist whose Nature cover paper first demonstrated that AI could match dermatologists at diagnosing skin cancer, Esteva has co-founded four companies with a combined market cap of $2.2B. Named to TIME100 Health 2025 and Modern Healthcare's 40 Under 40 for 2025, he leads a company that raised $175M total and was named a TIME 2024 Best Invention.